SCHEMBL718034

SCHEMBL718034

Cc1cccc2cc([C@H](C)NC(=O)OC(C)(C)C)c(N3CCOCC3)nc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.40
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HTT P42858 1/20 0.40
PIK3CD O00329 2/20 0.39
BRD4 O60885 2/20 0.39
ALOX15 P16050 2/20 0.38
NPC1 O15118 1/20 0.38
NR1I2 O75469 1/20 0.38
USP2 O75604 1/20 0.38
TP53 P04637 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
TSHR P16473 2/20 0.38
OPRK1 P41145 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL722794 0.91 TSHR (0.46) KDM4EALDH1A1SMN1; SMN2PIK3CDALOX15
SCHEMBL15875817 0.82 PDE10A (0.44) PIK3CD
SCHEMBL17530819 0.82 PDE10A (0.44) PIK3CD
SCHEMBL713467 0.79 TSHR (0.43) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL863903 0.79 TSHR (0.43) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL717045 0.77 PIK3CB (0.40) MEN1KMT2AKDM4EALDH1A1PIK3CD
SCHEMBL716547 0.76 TDP1 (0.44) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL716288 0.76 DRD2 (0.40) MEN1KMT2ASMN1; SMN2TP53
SCHEMBL715545 0.75 TSHR (0.41) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL715190 0.74 MAPK1 (0.36) KMT2AMAPTPIK3CDTP53L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 MEN1 3000/4885KMT2A 1670/4885KDM4E 2430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.